Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BMS/AbbVie Empliciti Leaps Ahead, Wins Fast FDA Nod

This article was originally published in Scrip

Executive Summary

The FDA has been on a roll in granting early approvals of drugs to treat multiple myeloma – giving its nod to three new products in just the past couple of weeks well ahead of their Prescription Drug User Fee Act (PDUFA) goal dates, with Bristol-Myers Squibb Co.'s and AbbVie Inc.'s Empliciti (elotuzumab) being the latest.

You may also be interested in...



Karyopharm’s Xpovio In Multiple Myeloma Priced At $22,000 Per Four-Week Cycle

Immediate interaction with US FDA after stressful advisory committee facilitated accelerated approval in fourth-line myeloma, company says. Four different dosing regimens will be priced at $22,000 for four weeks.

Expanded US Approval Set To Take Janssen’s Darzalex Higher

Janssen’s multiple myeloma therapy, Darzalex, has won an additional US approval for use earlier in the treatment paradigm, building momentum for a product that has already got off to a strong start.

Janssen Oncology Strategy: Take A Holistic Approach To R&D

With Darzalex in the spotlight at the ASCO annual meeting, J&J highlights its comprehensive focus on trio of disease areas – hematology, prostate cancer and lung cancer.

Topics

UsernamePublicRestriction

Register

LL1132440

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel